File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients
  • Basic View
  • Metadata View
  • XML View
TitleOverexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients
 
AuthorsHe, LR2
Zhao, HY2
Li, BK2
Liu, YH1
Liu, MZ2
Guan, XY2
Bian, XW3
Zeng, YX2
Xie, D2
 
Keywordsamplification
eIF5A-2
immunohistochemistry
non-small cell lung carcinoma
prognosis
 
Issue Date2011
 
PublisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
 
CitationInternational Journal Of Cancer, 2011, v. 129 n. 1, p. 143-150 [How to Cite?]
DOI: http://dx.doi.org/10.1002/ijc.25669
 
AbstractWe have previously isolated an oncogene EIF5A2 (eukaryotic initiation factor 5A2) from a frequently amplified region at 3q of a primary ovarian cancer cell line, and demonstrated its impact on prognosis in human ovarian cancer. Amplification of chromosome 3q has also been detected frequently in non-small cell lung cancer (NSCLC), however, abnormalities of EIF5A2 and its clinicopathologic significance in NSCLC haven't been studied. In our study, the methods of immunohistochemistry and fluorescence in situ hybridization were utilized to examine protein expression and amplification of EIF5A2 in 248 surgically resected NSCLCs (learning cohort) and another validation cohort of 120 stage I NSCLC patients. Overexpression and amplification of EIF5A2 was detected informatively in 48.7% and 13.7% of NSCLCs in learning cohort, 33.3% and 6.0% of NSCLCs in validation cohort. Overexpression of eIF5A-2 was found to correlate with gene amplification, increased cell proliferation and advanced T stage. In learning cohort, eIF5A-2 expression was evaluated as a strong prognostic factor on disease-specific survival, but in subgroup analyses, it only retained its stratified significance in stage I set (Hazards ratio = 2.799, p = 0.001). In validation cohort, the impact of eIF5A-2 expression on survival in stage I NSCLC patients was also observed (Hazard ratio = 2.097, p = 0.014). Our findings suggested that overexpression of eIF5A-2 correlates with local invasion of NSCLC, and might serve as an adverse prognostic marker of survival for stage I NSCLC patients. Copyright © 2010 UICC.
 
ISSN0020-7136
2013 Impact Factor: 5.007
 
DOIhttp://dx.doi.org/10.1002/ijc.25669
 
ISI Accession Number IDWOS:000289987300014
Funding AgencyGrant Number
Nature Science Foundation of China30972884
973 Project of China2010CB529401
2010CB91280
Funding Information:

Grant sponsor: Nature Science Foundation of China; Grant number: 30972884; Grant sponsor: 973 Project of China; Grant numbers: 2010CB529401, 2010CB91280

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorHe, LR
 
dc.contributor.authorZhao, HY
 
dc.contributor.authorLi, BK
 
dc.contributor.authorLiu, YH
 
dc.contributor.authorLiu, MZ
 
dc.contributor.authorGuan, XY
 
dc.contributor.authorBian, XW
 
dc.contributor.authorZeng, YX
 
dc.contributor.authorXie, D
 
dc.date.accessioned2011-08-26T14:22:12Z
 
dc.date.available2011-08-26T14:22:12Z
 
dc.date.issued2011
 
dc.description.abstractWe have previously isolated an oncogene EIF5A2 (eukaryotic initiation factor 5A2) from a frequently amplified region at 3q of a primary ovarian cancer cell line, and demonstrated its impact on prognosis in human ovarian cancer. Amplification of chromosome 3q has also been detected frequently in non-small cell lung cancer (NSCLC), however, abnormalities of EIF5A2 and its clinicopathologic significance in NSCLC haven't been studied. In our study, the methods of immunohistochemistry and fluorescence in situ hybridization were utilized to examine protein expression and amplification of EIF5A2 in 248 surgically resected NSCLCs (learning cohort) and another validation cohort of 120 stage I NSCLC patients. Overexpression and amplification of EIF5A2 was detected informatively in 48.7% and 13.7% of NSCLCs in learning cohort, 33.3% and 6.0% of NSCLCs in validation cohort. Overexpression of eIF5A-2 was found to correlate with gene amplification, increased cell proliferation and advanced T stage. In learning cohort, eIF5A-2 expression was evaluated as a strong prognostic factor on disease-specific survival, but in subgroup analyses, it only retained its stratified significance in stage I set (Hazards ratio = 2.799, p = 0.001). In validation cohort, the impact of eIF5A-2 expression on survival in stage I NSCLC patients was also observed (Hazard ratio = 2.097, p = 0.014). Our findings suggested that overexpression of eIF5A-2 correlates with local invasion of NSCLC, and might serve as an adverse prognostic marker of survival for stage I NSCLC patients. Copyright © 2010 UICC.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationInternational Journal Of Cancer, 2011, v. 129 n. 1, p. 143-150 [How to Cite?]
DOI: http://dx.doi.org/10.1002/ijc.25669
 
dc.identifier.doihttp://dx.doi.org/10.1002/ijc.25669
 
dc.identifier.epage150
 
dc.identifier.hkuros190868
 
dc.identifier.isiWOS:000289987300014
Funding AgencyGrant Number
Nature Science Foundation of China30972884
973 Project of China2010CB529401
2010CB91280
Funding Information:

Grant sponsor: Nature Science Foundation of China; Grant number: 30972884; Grant sponsor: 973 Project of China; Grant numbers: 2010CB529401, 2010CB91280

 
dc.identifier.issn0020-7136
2013 Impact Factor: 5.007
 
dc.identifier.issue1
 
dc.identifier.pmid20830705
 
dc.identifier.scopuseid_2-s2.0-79955446362
 
dc.identifier.spage143
 
dc.identifier.urihttp://hdl.handle.net/10722/137270
 
dc.identifier.volume129
 
dc.languageeng
 
dc.publisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
 
dc.publisher.placeUnited States
 
dc.relation.ispartofInternational Journal of Cancer
 
dc.relation.referencesReferences in Scopus
 
dc.rightsInternational Journal of Cancer. Copyright © John Wiley & Sons, Inc..
 
dc.subject.meshCarcinoma, Non-Small-Cell Lung - genetics - pathology
 
dc.subject.meshImmunohistochemistry
 
dc.subject.meshLung Neoplasms - genetics - pathology
 
dc.subject.meshPeptide Initiation Factors - genetics
 
dc.subject.meshSurvival Analysis
 
dc.subjectamplification
 
dc.subjecteIF5A-2
 
dc.subjectimmunohistochemistry
 
dc.subjectnon-small cell lung carcinoma
 
dc.subjectprognosis
 
dc.titleOverexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>He, LR</contributor.author>
<contributor.author>Zhao, HY</contributor.author>
<contributor.author>Li, BK</contributor.author>
<contributor.author>Liu, YH</contributor.author>
<contributor.author>Liu, MZ</contributor.author>
<contributor.author>Guan, XY</contributor.author>
<contributor.author>Bian, XW</contributor.author>
<contributor.author>Zeng, YX</contributor.author>
<contributor.author>Xie, D</contributor.author>
<date.accessioned>2011-08-26T14:22:12Z</date.accessioned>
<date.available>2011-08-26T14:22:12Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>International Journal Of Cancer, 2011, v. 129 n. 1, p. 143-150</identifier.citation>
<identifier.issn>0020-7136</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/137270</identifier.uri>
<description.abstract>We have previously isolated an oncogene EIF5A2 (eukaryotic initiation factor 5A2) from a frequently amplified region at 3q of a primary ovarian cancer cell line, and demonstrated its impact on prognosis in human ovarian cancer. Amplification of chromosome 3q has also been detected frequently in non-small cell lung cancer (NSCLC), however, abnormalities of EIF5A2 and its clinicopathologic significance in NSCLC haven&apos;t been studied. In our study, the methods of immunohistochemistry and fluorescence in situ hybridization were utilized to examine protein expression and amplification of EIF5A2 in 248 surgically resected NSCLCs (learning cohort) and another validation cohort of 120 stage I NSCLC patients. Overexpression and amplification of EIF5A2 was detected informatively in 48.7% and 13.7% of NSCLCs in learning cohort, 33.3% and 6.0% of NSCLCs in validation cohort. Overexpression of eIF5A-2 was found to correlate with gene amplification, increased cell proliferation and advanced T stage. In learning cohort, eIF5A-2 expression was evaluated as a strong prognostic factor on disease-specific survival, but in subgroup analyses, it only retained its stratified significance in stage I set (Hazards ratio = 2.799, p = 0.001). In validation cohort, the impact of eIF5A-2 expression on survival in stage I NSCLC patients was also observed (Hazard ratio = 2.097, p = 0.014). Our findings suggested that overexpression of eIF5A-2 correlates with local invasion of NSCLC, and might serve as an adverse prognostic marker of survival for stage I NSCLC patients. Copyright &#169; 2010 UICC.</description.abstract>
<language>eng</language>
<publisher>John Wiley &amp; Sons, Inc.. The Journal&apos;s web site is located at http://www3.interscience.wiley.com/journal/29331/home</publisher>
<relation.ispartof>International Journal of Cancer</relation.ispartof>
<rights>International Journal of Cancer. Copyright &#169; John Wiley &amp; Sons, Inc..</rights>
<subject>amplification</subject>
<subject>eIF5A-2</subject>
<subject>immunohistochemistry</subject>
<subject>non-small cell lung carcinoma</subject>
<subject>prognosis</subject>
<subject.mesh>Carcinoma, Non-Small-Cell Lung - genetics - pathology</subject.mesh>
<subject.mesh>Immunohistochemistry</subject.mesh>
<subject.mesh>Lung Neoplasms - genetics - pathology</subject.mesh>
<subject.mesh>Peptide Initiation Factors - genetics</subject.mesh>
<subject.mesh>Survival Analysis</subject.mesh>
<title>Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1002/ijc.25669</identifier.doi>
<identifier.pmid>20830705</identifier.pmid>
<identifier.scopus>eid_2-s2.0-79955446362</identifier.scopus>
<identifier.hkuros>190868</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-79955446362&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>129</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>143</identifier.spage>
<identifier.epage>150</identifier.epage>
<identifier.isi>WOS:000289987300014</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. Guangdong Provincial People's Hospital
  2. Sun Yat-Sen University
  3. Third Military Medical University